Testing drug sensitivity in EGFR-mutant lung cancer cells
Part of Cancer, Lungs & breathing clinical trials.
This study uses leftover tissue samples from people with EGFR-mutant non-small cell lung cancer to test how well different drugs work against their tumor cells. It may help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (NSCLC).
- Your tumor has an EGFR mutation (a specific genetic change).
- You have leftover tissue from a biopsy or surgery that can be used for testing.
- You sign a consent form agreeing to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world treatment for non-small cell lung cancer with a specific genetic change (EGFR mutation). It might help researchers understand how different treatments work in daily practice.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
This study tests if regular blood tests can help guide chemotherapy treatment before surgery for people with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It aims to see if these blood tests can show how well the cancer is responding, potentially allowing doctors to adjust treatment for better outcomes.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.